Penumbra Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 19/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 313.05.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Penumbra Inc's Score
Industry at a Glance
Industry Ranking
19 / 208
Overall Ranking
82 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
20
analysts
Buy
Current Rating
313.053
Target Price
+6.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Penumbra Inc Highlights
StrengthsRisks
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.02% year-on-year.
Undervalued
The company’s latest PE is 74.72, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.12M shares, decreasing 7.80% quarter-over-quarter.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Ticker SymbolPEN
CompanyPenumbra Inc
CEOElsesser (Adam)
Websitehttps://www.penumbrainc.com/
FAQs
What is the current price of Penumbra Inc (PEN)?
The current price of Penumbra Inc (PEN) is 316.050.
What is the symbol of Penumbra Inc?
The ticker symbol of Penumbra Inc is PEN.
What is the 52-week high of Penumbra Inc?
The 52-week high of Penumbra Inc is 320.000.
What is the 52-week low of Penumbra Inc?
The 52-week low of Penumbra Inc is 221.260.
What is the market capitalization of Penumbra Inc?
The market capitalization of Penumbra Inc is 12.37B.
What is the net income of Penumbra Inc?
The net income of Penumbra Inc is 14.01M.
Is Penumbra Inc (PEN) currently rated as Buy, Hold, or Sell?
According to analysts, Penumbra Inc (PEN) has an overall rating of Buy, with a price target of 313.053.
What is the Earnings Per Share (EPS TTM) of Penumbra Inc (PEN)?
The Earnings Per Share (EPS TTM) of Penumbra Inc (PEN) is 4.228.